Abstract
Energy homeostasis in mammalians is a teleological process regulated by the interplay between caloric intake and energy expenditure. Incretins are a significant component of the complex homeostatic network regulating the metabolic state in humans. This narrative review will focus on the basic concepts regarding incretins physiology and their regulatory feedback mechanisms affecting energy homeostasis. In this context, glucagon-like peptide 1 (GLP-1) promotes satiety and weight loss through centrally and peripherally mediated pathways. On the other hand, gastric inhibitory peptide (GIP) is implicated in energy storage by its actions on adipose tissue. Understanding this biological model requires a holistic approach, since it is dually manifested by promoting weight reduction, in the case of GLP-1, or favoring lipid accumulation, in the case of GIP. The complete spectrum of incretin actions related to energy homeostasis is yet to be fully elucidated. Currently, new drugs based on incretin physiology are available for treatment of type 2 diabetes mellitus, whereas the implication of similar drugs in the treatment of obesity is under investigation. These agents exert several beneficial effects that minimize cardiovascular risk.
Keywords: Energy homeostasis, glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), incretins, obesity, type 2 diabetes mellitus
Current Vascular Pharmacology
Title:The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Volume: 10 Issue: 6
Author(s): Spyridon Karras, Dimitrios G. Goulis, Gesthimani Mintziori, Niki Katsiki and Themistoklis Tzotzas
Affiliation:
Keywords: Energy homeostasis, glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP), incretins, obesity, type 2 diabetes mellitus
Abstract: Energy homeostasis in mammalians is a teleological process regulated by the interplay between caloric intake and energy expenditure. Incretins are a significant component of the complex homeostatic network regulating the metabolic state in humans. This narrative review will focus on the basic concepts regarding incretins physiology and their regulatory feedback mechanisms affecting energy homeostasis. In this context, glucagon-like peptide 1 (GLP-1) promotes satiety and weight loss through centrally and peripherally mediated pathways. On the other hand, gastric inhibitory peptide (GIP) is implicated in energy storage by its actions on adipose tissue. Understanding this biological model requires a holistic approach, since it is dually manifested by promoting weight reduction, in the case of GLP-1, or favoring lipid accumulation, in the case of GIP. The complete spectrum of incretin actions related to energy homeostasis is yet to be fully elucidated. Currently, new drugs based on incretin physiology are available for treatment of type 2 diabetes mellitus, whereas the implication of similar drugs in the treatment of obesity is under investigation. These agents exert several beneficial effects that minimize cardiovascular risk.
Export Options
About this article
Cite this article as:
Karras Spyridon, G. Goulis Dimitrios, Mintziori Gesthimani, Katsiki Niki and Tzotzas Themistoklis, The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity, Current Vascular Pharmacology 2012; 10 (6) . https://dx.doi.org/10.2174/157016112803520909
DOI https://dx.doi.org/10.2174/157016112803520909 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Polymorphic N-Acetyltransferases on Non-Malignant Spontaneous Disorders and on Response to Drugs
Current Drug Metabolism Comparison of Amniotic Fluid Index and Single Deepest Vertical Pocket
Current Women`s Health Reviews Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Hypovitaminosis D is Associated with Endothelial Dysfunction in Patients with Metabolic Syndrome
Current Vascular Pharmacology Editorial [Hot Topic: Plasminogen Activator Inhibitor-1 (Guest Editor: Daniel A. Lawrence)]
Current Drug Targets Diagnosis of Gout: Considering Clinical and Research Settings
Current Rheumatology Reviews Right Heart Catheterization Through Persistent Left Superior Vena Cava, an Extremely Rare Procedure and Review of Current Literature
Current Cardiology Reviews Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors
Current Medicinal Chemistry Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art
Current Medicinal Chemistry Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Surrogates of Insulin Sensitivity and Indices of Cardiometabolic Profile in Obesity
Current Vascular Pharmacology A Review on Molecular Mechanism of Flavonoids as Antidiabetic Agents
Mini-Reviews in Medicinal Chemistry Hepatic Effects of Duloxetine – III: Analysis of Hepatic Events Using External Data Sources
Current Drug Safety Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Current Drug Targets Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design